Sponsor Dossier
Novo Nordisk Pharmaceuticals
Sponsor Dossier for Novo Nordisk Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTRAPID
- Brand: ALHEMO
- Brand: AWIQLI
- Brand: ESPEROCT
- Brand: ESTROFEM
- Brand: FIASP
- Brand: GLUCAGEN
- Brand: KLIOGEST
- Device (sponsor): Cartridge-accepting autoinjector, mechanical
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
- Device (sponsor): Needle, injector, medication/vaccine
- Device (sponsor): Injector, medication/vaccine, needle
- Device (sponsor): Needle guard
- Device (sponsor): Needle introducer
- Device (sponsor): Injector, medication/vaccine, needle
About
Novo Nordisk Pharmaceuticals is an Australian Private Company with ABN 40002879996, registered in New South Wales. The entity is active.
Portfolio
Novo Nordisk Pharmaceuticals has 31 brands on the ARTG, of which 29 are indexable and 23 carry a Product Information document. 12 brands are PBS-listed, 8 have a PBAC outcome on record, and 16 have an AusPAR on record. Notable brands include ACTRAPID, ALHEMO, AWIQLI, ESPEROCT, ESTROFEM, FIASP, GLUCAGEN, KLIOGEST, KLIOVANCE, LEVEMIR, MIXTARD, NORDITROPIN FLEXPRO.
Therapeutic focus
— Endocrinology: 23 brands — Haematology: 5 brands — Reproductive Health: 3 brands
PBS footprint
12 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-11-01, across 8 brands with a PBAC outcome on record. The latest AusPAR is 2025-07-14, across 16 brands with an AusPAR on record.